Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) filings page on Stock Titan is designed to organize and interpret regulatory information related to this preferred equity and its issuer, Bruker Corporation. While no specific SEC filings are listed here in the available data, Bruker’s public communications provide important context for understanding BRKRP as a mandatory convertible preferred security with a stated dividend rate of 6.375%.
In its announcements, Bruker has disclosed a quarterly cash dividend of $3.6745 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Regulatory filings associated with such securities typically include the original registration statements and prospectus describing the preferred stock terms, including dividend provisions, conversion mechanics, and rights relative to common stock. Periodic reports often discuss capital structure, preferred stock dividends, and any changes affecting holders of BRKRP.
For a company like Bruker, which emphasizes high-performance scientific instruments and analytical and diagnostic solutions, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can also provide narrative and quantitative detail on its operations in post-genomic life science research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, semiconductor metrology, and clinical and molecular diagnostics. These documents help place the BRKRP preferred stock within the broader financial and operational picture of the issuer.
On Stock Titan, AI-powered tools can assist in summarizing lengthy filings, highlighting sections that relate to preferred stock terms, dividend policies, and capital structure, as well as identifying disclosures relevant to Bruker’s scientific and diagnostic activities. This can help readers more quickly locate information that matters for evaluating BRKRP and understanding how regulatory disclosures reflect Bruker’s business and financing choices.
A holder of BRKR common stock has filed a notice to sell 2,000 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $73,880. The shares are listed on NASDAQ, and the filing states 151,941,144 shares of this class are outstanding.
The 2,000 shares to be sold were acquired on 02/13/2026 via a stock option exercise from the issuer, paid in cash the same day. The person named in recent activity, Mark R. Munch, has already sold common shares in the past three months, including 2,000 shares on 01/15/2026 for $98,400, 7,000 shares on 01/12/2026 for $385,000, and 33,843 shares on 01/05/2026 for $1,680,704.
Bruker Corporation reported a challenging 2025, with modest growth but weaker profitability and a GAAP loss. Full-year revenue rose to $3.44 billion, up 2.1% from 2024, yet organic revenue fell 3.7%. Q4-25 revenue was $977.2 million, essentially flat year-over-year.
GAAP operating income dropped to $68.2 million for 2025 from $253.1 million, driven by $127.2 million of goodwill and intangible impairments and $77.4 million of restructuring charges. GAAP diluted loss per share was $(0.15), while non-GAAP diluted EPS was $1.83, down from $2.41.
Management initiated 2026 guidance calling for revenue of $3.57–$3.60 billion, implying 4%–5% growth, with 1%–2% organic growth and non-GAAP EPS of $2.10–$2.15, 15%–17% above 2025 despite an estimated 8% foreign-exchange headwind.